Cargando…

Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta

INTRODUCTION: In patients with Parkinson’s disease (PD), low cerebrospinal fluid (CSF) amyloid beta 1-42 (Ab42) at baseline is the most consistent CSF biomarker as a risk factor for developing dementia. Low CSF Ab42 is, however, a typical hallmark of Alzheimer’s disease (AD). Hence, low CSF Ab42 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tufekcioglu, Zeynep, Lange, Johannes, Pedersen, Kenn Freddy, Tysnes, Ole-Bjørn, Alves, Guido, Emre, Murat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645440/ https://www.ncbi.nlm.nih.gov/pubmed/38025590 http://dx.doi.org/10.1159/000534552

Ejemplares similares

Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease
por: Oftedal, Linn, et al.
Publicado: (2023)

Evolution of impulsive–compulsive behaviors and cognition in Parkinson’s disease
por: Erga, Aleksander H., et al.
Publicado: (2019)

Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease
por: Oftedal, Linn, et al.
Publicado: (2023)

Impulsive and Compulsive Behaviors in Parkinson’s Disease: The Norwegian ParkWest Study
por: Erga, Aleksander H., et al.
Publicado: (2017)

Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s Disease
por: Erga, Aleksander H., et al.
Publicado: (2018)

Seed Amplification Assay as a Diagnostic Tool in Newly-Diagnosed Parkinson’s Disease
por: Oftedal, Linn, et al.
Publicado: (2023)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
por: Said, Harun Muayad, et al.
Publicado: (2022)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders
por: Pedersen, Camilla Christina, et al.
Publicado: (2023)

Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease
por: Bjornestad, Anders, et al.
Publicado: (2016)

COVID-19 infection presented as severe dyskinesia in a patient with Parkinson’s disease: a case with daily video recording
por: Gultekin, Murat, et al.
Publicado: (2022)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Parkinson’s disease clinical milestones and mortality
por: Gonzalez, Maria Camila, et al.
Publicado: (2022)

Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease
por: Ibanez, Laura, et al.
Publicado: (2020)

Altered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson’s disease
por: Dick, Fiona, et al.
Publicado: (2023)

Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease
por: Fonteh, Alfred N., et al.
Publicado: (2015)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Cerebrospinal fluid catecholamines in delirium and dementia
por: Henjum, Kristi, et al.
Publicado: (2021)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

An Aged Canid with Behavioral Deficits Exhibits Blood and Cerebrospinal Fluid Amyloid Beta Oligomers
por: Rusbridge, Clare, et al.
Publicado: (2018)

Amyloid‐beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome
por: Stylianaki, Ioanna, et al.
Publicado: (2020)

The Major Components of Cerebrospinal Fluid Dictate the Characteristics of Inhibitors against Amyloid-Beta Aggregation
por: Sakalauskas, Andrius, et al.
Publicado: (2023)

Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients
por: Szwedo, Aleksandra A., et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex
por: Nakayama, Yui, et al.
Publicado: (2013)

Differential transcript usage in the Parkinson’s disease brain
por: Dick, Fiona, et al.
Publicado: (2020)

Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population
por: Lange, Johannes, et al.
Publicado: (2015)

The Relationship between Different Assays for Detection and Quantification of Amyloid Beta 42 in Human Cerebrospinal Fluid
por: Ellis, Teresa A., et al.
Publicado: (2012)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer's Disease
por: Sun, Hao-Lun, et al.
Publicado: (2018)

Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women
por: Haapalinna, Fanni, et al.
Publicado: (2016)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
por: Rahhal, Samar, et al.
Publicado: (2023)

Heteromers of amyloid precursor protein in cerebrospinal fluid
por: Cuchillo-Ibañez, Inmaculada, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
por: Banerjee, Gargi, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy
por: Sembill, Jochen A, et al.
Publicado: (2023)

Beta-amyloid imaging in dementia
por: Chun, Kyung Ah
Publicado: (2018)

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?
por: Weston, Philip S.J., et al.
Publicado: (2016)

Early Forms of α-Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson’s Disease
por: Flønes, Irene Hana, et al.
Publicado: (2022)

Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease
por: Maple-Grødem, Jodi, et al.
Publicado: (2021)

Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
por: Han, Jiajun, et al.
Publicado: (2021)

Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition
por: Nido, Gonzalo S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n6huk5lrpptq7h1b47t823b95r